Exane Derivatives’s TG Therapeutics TGTX Stock Holding History

Exane Derivatives’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,645	Closed	-$53.7K	–	927
2022 Q1	$53.7K	Buy	+5,645	New	+$65.3K	0.02%	562
2021 Q4	–	Sell	-5,368	Closed	-$179K	–	976
2021 Q3	$179K	Sell	5,368 -3,563	-40%	-$110K	0.04%	419
2021 Q2	$346K	Hold	8,931	–	–	0.08%	254
2021 Q1	$430K	Sell	8,931 -2,651	-23%	-$127K	0.12%	165
2020 Q4	$602K	Buy	11,582 +1,288	+13%	+$43.5K	0.18%	121
2020 Q3	$275K	Sell	10,294 -4,286	-29%	-$98.6K	0.08%	184
2020 Q2	$284K	Sell	14,580 -3,858	-21%	-$62.1K	0.08%	194
2020 Q1	$181K	Buy	18,438 +18,003	+4,139%	+$227K	0.05%	211
2019 Q4	$6.13K	Hold	435	–	–	﹤0.01%	427
2019 Q3	$2.44K	Hold	435	–	–	﹤0.01%	476
2019 Q2	$3.76K	Hold	435	–	–	﹤0.01%	489
2019 Q1	$3.5K	Hold	435	–	–	﹤0.01%	422
2018 Q4	$1.78K	Hold	435	–	–	﹤0.01%	531
2018 Q3	$2.64K	Sell	435 -9,399	-96%	-$107K	﹤0.01%	481
2018 Q2	$132K	Hold	9,834	–	–	0.02%	303
2018 Q1	$139K	Buy	+9,834	New	+$126K	0.03%	262

Other funds holding TGTX

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exane Derivatives's TGTX Position: Q2 2022 in Review

Exane Derivatives sold out of TG Therapeutics (TGTX) in Q2 2022, closing a stake of 5,645 shares — an estimated $53.7K sold.

Exane Derivatives first reported a position in TGTX in Q1 2018 and held it in 16 quarters. The position peaked at $602K in Q4 2020. 174 funds tracked by Wall St. Rank hold TGTX as of Q2 2022.

Exane Derivatives reported no remaining TG Therapeutics position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 5,645 TG Therapeutics shares in Q2 2022, an estimated $53.7K.
Exane Derivatives first reported a position in TG Therapeutics in Q1 2018 and held it in 16 quarters.
Exane Derivatives's TG Therapeutics position peaked at $602K in Q4 2020.
174 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.